A review of clinical trials in GBA1-associated Parkinson's disease that argues for implementing molecular classification to improve trial design and therapeutic targeting.

Emphasizing GBA1-linked lysosomal dysfunction and the need for molecular stratification is directly relevant to targeting glucocerebrosidase pathways and developing biomarker-guided, disease-modifying therapies for PD.